SCHEMBL19486395

SCHEMBL19486395

O=C(C1CCC1)N1CCN(c2ccnn3cc(-c4ccccc4)cc23)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FASN P49327 1/20 0.48
IDE P14735 1/20 0.47
TSHR P16473 3/20 0.47
RUVBL1 Q9Y265 1/20 0.47
JAK1 P23458 5/20 0.46
JAK3 P52333 5/20 0.46
JAK2 O60674 1/20 0.46
TYK2 P29597 1/20 0.46
MAPK1 P28482 2/20 0.44
CNR1 P21554 1/20 0.44
CKS1B P61024 1/20 0.44
SKP1 P63208 1/20 0.44
SKP2 Q13309 1/20 0.44
POLB P06746 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPT P10636 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19486467 0.97 TSHR (0.52) FASNIDETSHRRUVBL1JAK1
SCHEMBL19486826 0.96 RUVBL1 (0.48) FASNIDETSHRRUVBL1JAK1
SCHEMBL19481743 0.87 MAPT (0.47) IDETSHRRUVBL1MAPK1POLB
SCHEMBL19459013 0.86 IDE (0.43) IDETSHRRUVBL1MAPK1CKS1B
SCHEMBL19481702 0.86 MAPT (0.44) IDETSHRRUVBL1MAPK1POLB
SCHEMBL19458940 0.86 ALDH1A1 (0.44) FASNIDETSHRRUVBL1JAK1
SCHEMBL19459217 0.86 ALDH1A1 (0.44) IDETSHRRUVBL1MAPK1CKS1B
SCHEMBL19482433 0.85 TDP1 (0.46) IDETSHRRUVBL1MAPK1POLB
SCHEMBL19481808 0.85 MAPT (0.45) IDETSHRRUVBL1POLBMEN1
SCHEMBL25802853 0.84 IDE (0.40) FASNIDETSHRJAK1JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10233186-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2019-03-19 US disclosed
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2017-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10233186-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 FASN 1447/4885IDE 317/4885TSHR 780/4885
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 FASN 1159/4885IDE 333/4885TSHR 1171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.